Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Provided By GlobeNewswire
Last update: May 14, 2025
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided business highlights.
Read more at globenewswire.com
